Health and Healthcare

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

1254 Articles

Jon C. Ogg | Aug 2, 2017 at 1:20 PM EDT

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its…

Paul Ausick | Jul 24, 2017 at 4:01 PM EDT

GE, Nike Guide DJIA Down on Monday

General Electric, Nike, Home Depot, and Johnson & Johnson led the DJIA lower Monday.

Jon C. Ogg | Jul 21, 2017 at 9:16 AM EDT

Top Analyst Upgrades & Downgrades: American Superconductor, Chipotle, Groupon, J&J, Juniper, Occidental, Wells Fargo and Many More

Stocks have pulled back a tad from all-time highs, and the market indexes were indicated to have a slight drop…

Chris Lange | Jul 21, 2017 at 8:37 AM EDT

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the…

Jon C. Ogg | Jul 20, 2017 at 9:24 AM EDT

Top Analyst Upgrades and Downgrades: BHP Billiton, HP, Kinder Morgan, Marathon Petroleum, Nike, Pfizer, Rite Aid, Tesla and More

Stocks were indicated marginally higher on Thursday after the European Central Bank statement remained quite dovish. The major equity indexes…

Chris Lange | Jul 18, 2017 at 9:58 AM EDT

Johnson & Johnson Shares Slip Following Mixed Earnings

Johnson & Johnson (NYSE: JNJ) released its fiscal second-quarter earnings report before the markets opened on Tuesday. The company posted…

Chris Lange | Jul 15, 2017 at 10:25 AM EDT

Goldman Sachs, IBM and More Dow Stocks Reporting Next Week

24/7 Wall St. has put together a preview of General Electric, Microsoft and other Dow Jones Industrial Average companies scheduled…

Paul Ausick | Jun 22, 2017 at 4:01 PM EDT

Goldman Sachs, Wal-Mart Weigh on DJIA Thursday

Johnson & Johnson and Merck were the top performers among the Dow 30 stocks Thursday while Goldman Sachs and Wal-Mart…

Jon C. Ogg | Jun 22, 2017 at 12:10 PM EDT

The Top 20 S&P 500 Companies Buying Back Stock in 2017

These are the top 20 stock buybacks in dollars spent during the first quarter of 2017 of all S&P 500…

Jon C. Ogg | Jun 14, 2017 at 2:00 PM EDT

Is the Dow Less Than 1% Away From Its 2017 Peak?

With a Federal Reserve rate hike decision, investors have to keep in mind what to think of the stock market…

Paul Ausick | Jun 2, 2017 at 4:01 PM EDT

Boeing, 3M Dominate the DJIA Friday

Boeing, 3M, Johnson & Johnson, and Visa all posted new 52-week highs Friday to lead the DJIA's gain for the…

Jon C. Ogg | May 31, 2017 at 10:40 AM EDT

Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News

When companies see their shares rise almost 50%, investors probably just assume the news is from a buyout or a…

Chris Lange | May 30, 2017 at 9:30 AM EDT

Why Protagonist Therapeutics Shares Are Climbing

Protagonist Therapeutics saw its shares make a solid gain early on Tuesday after the company announced a key worldwide licensing…

Paul Ausick | May 26, 2017 at 4:01 PM EDT

Home Depot, Johnson & Johnson Drag DJIA Lower Friday

The DJIA is trading narrowly lower just minutes before Friday's closing bell. Home Depot and J&J are leading the losers,…

Jon C. Ogg | May 15, 2017 at 5:13 PM EDT

Warren Buffett’s Top Stock Holdings Keep Changing

If Warren Buffett is considered the greatest investor of the modern era, and if he has held the title of…

1 … 39 40 41 42 43 … 84

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

GE, Nike Guide DJIA Down on Monday

Top Analyst Upgrades & Downgrades: American Superconductor, Chipotle, Groupon, J&J, Juniper, Occidental, Wells Fargo and Many More

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Top Analyst Upgrades and Downgrades: BHP Billiton, HP, Kinder Morgan, Marathon Petroleum, Nike, Pfizer, Rite Aid, Tesla and More

Johnson & Johnson Shares Slip Following Mixed Earnings

Goldman Sachs, IBM and More Dow Stocks Reporting Next Week

Goldman Sachs, Wal-Mart Weigh on DJIA Thursday

The Top 20 S&P 500 Companies Buying Back Stock in 2017

Is the Dow Less Than 1% Away From Its 2017 Peak?

Boeing, 3M Dominate the DJIA Friday

Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News

Why Protagonist Therapeutics Shares Are Climbing

Home Depot, Johnson & Johnson Drag DJIA Lower Friday

Warren Buffett’s Top Stock Holdings Keep Changing

QYLD’s $10,000 Problem: How a Covered-Call ETF Left Investors With a Fraction of Nasdaq Gains

The HSA Move High Earners Are Prioritizing Over 401(k) Catch-Up Contributions in 2026

The $82 Annual Fee Is Just the Start: TQQQ’s Hidden Cost Structure Explained

The HSA Move High Earners Are Prioritizing Over 401(k) Catch-Up Contributions in 2026

Your First Required IRA Withdrawal at 73 Can Push You Past the IRMAA Cliff for a Full Year

QYLD’s $10,000 Problem: How a Covered-Call ETF Left Investors With a Fraction of Nasdaq Gains

The HSA Move High Earners Are Prioritizing Over 401(k) Catch-Up Contributions in 2026

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

GE, Nike Guide DJIA Down on Monday

Top Analyst Upgrades & Downgrades: American Superconductor, Chipotle, Groupon, J&J, Juniper, Occidental, Wells Fargo and Many More

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Top Analyst Upgrades and Downgrades: BHP Billiton, HP, Kinder Morgan, Marathon Petroleum, Nike, Pfizer, Rite Aid, Tesla and More

Johnson & Johnson Shares Slip Following Mixed Earnings

Goldman Sachs, IBM and More Dow Stocks Reporting Next Week

Goldman Sachs, Wal-Mart Weigh on DJIA Thursday

The Top 20 S&P 500 Companies Buying Back Stock in 2017

Is the Dow Less Than 1% Away From Its 2017 Peak?

Boeing, 3M Dominate the DJIA Friday

Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News

Why Protagonist Therapeutics Shares Are Climbing

Home Depot, Johnson & Johnson Drag DJIA Lower Friday

Warren Buffett’s Top Stock Holdings Keep Changing

QYLD’s $10,000 Problem: How a Covered-Call ETF Left Investors With a Fraction of Nasdaq Gains

The HSA Move High Earners Are Prioritizing Over 401(k) Catch-Up Contributions in 2026

The $82 Annual Fee Is Just the Start: TQQQ’s Hidden Cost Structure Explained

Featured Reads

The HSA Move High Earners Are Prioritizing Over 401(k) Catch-Up Contributions in 2026

Your First Required IRA Withdrawal at 73 Can Push You Past the IRMAA Cliff for a Full Year